Global prevalence and disability burden of brain disorders: Impact of neurological, mental, and substance use disorders / Mohammad Ali Salehinejad, Ali Fathi Jouzdani, Igor D. Bandeira, Stephan Bender, Marom Bikson, Miguel Castelo-Branco, Roi Cohen Kadosh, Floriana Costanzo, Paul E. Croarkin, Pushpal Desarkar, Katherine Dyke, Simon Eickhoff, Paul B. Fitzgerald, Gesa Hartwigsen, Julian Koenig, Davide Martino, Deny Menghini, Fatemeh Sadat Mirfazeli, Vera Moliadze, Michael A. Nitsche, Lindsay M. Oberman, Michael Siniatchkin, Zahra Vaziri, Carmelo M. Vicario, Jaspe Vöckel, Miles Wischnewski, Carsten H. Wolters, Abraham Zangen, Tino Zaehle, Reza Zomorrodi, Andre R. Brunoni

Related documents

• Achieving minimal disease activity in atopic dermatitis is associated with fewer flares, reduced healthcare resource utilization, and improved disease control: analysis from the real-world MEASURE-AD study#1015167
• Potenziale und Grenzen Künstlicher Intelligenz in der klinisch-psychologischen Forschung, Lehre und Praxis#1015168
• Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21#1015169
• Sex- and menopause-related differences in immune and gastrointestinal symptom architecture in ME/CFS: evidence from factor analysis and structural equation modeling#1015170
• Transcatheter tricuspid valve annuloplasty vs edge-to-edge repair#1015171